This summit brings together over 250 key opinion leaders and senior industry experts in drug discovery, to discuss the latest innovative discovery strategies in different therapeutic areas as well as the most effective enabling technologies and solutions. Our co-located 5th Discovery 91AV & Drug Design Congress provides an unprecedented opportunity to gain insights from key presenters of the computational chemistry, discovery chemistry and medicinal field.
6 interactive streams:
Hosted by Tony De Fougerolles, Chief Scientific Officer at Ablynx
2. Open Innovation and partnerships for an improved Lead Generation
Hosted by Patrick Jimonet, External Opportunities in Drug Discovery, Sanofi
Download for free today: http://bit.ly/2efSZsv
For further information on the congress and the webinars, please contact Guillaume Alonso on g.alonso@oxfordglobal.co.uk or call +44 (0) 1865 248 455.
6 interactive streams:
- Drug Discovery Innovation and Strategies, Enabling Technologies
- Novel Drug Target Discovery for Immuno-Therapy, Autoimmune Diseases and Oncology
- Successful Phenotypic Drug Discovery: High Content Screening
- RNAi Screening, Cancer Genomics and Gene Editing for Drug Discovery
- Discovery 91AV, Medicinal and Computational 91AV
- Medicinal 91AV and Drug Design: Novel Approaches.
Free Webinar Recordings
1. Nanobodies as a Versatile and Clinically Validated Approach.Hosted by Tony De Fougerolles, Chief Scientific Officer at Ablynx
2. Open Innovation and partnerships for an improved Lead Generation
Hosted by Patrick Jimonet, External Opportunities in Drug Discovery, Sanofi
Download for free today: http://bit.ly/2efSZsv
For further information on the congress and the webinars, please contact Guillaume Alonso on g.alonso@oxfordglobal.co.uk or call +44 (0) 1865 248 455.
